Calcium in chronic kidney disease: myths and realities. Introduction.

@article{Langman2010CalciumIC,
  title={Calcium in chronic kidney disease: myths and realities. Introduction.},
  author={Craig B Langman and Jorge B Cannata-And{\'i}a},
  journal={Clinical journal of the American Society of Nephrology : CJASN},
  year={2010},
  volume={5 Suppl 1},
  pages={
          S1-2
        }
}
The kidneys, through proximal tubular active uptake or pass-through of filtered phosphorus, regulate phosphorus homeostasis in healthy individuals. Hormones and factors that contribute to the kidney regulation of phosphorus include parathyroid hormone, 1,25-dihydroxyvitamin D (1,25(OH)2D), and fibroblast growth factor-23 (FGF-23). However, in patients with progressive chronic kidney disease (CKD), the normal homeostatic mechanisms are challenged as FGF-23 and parathyroid hormone rise and 1,25… Expand

Paper Mentions

Interventional Clinical Trial
Background: Patient with stage 3 or 4 chronic kidney disease (CKD) usually has normal level of serum phosphate, due to increased serum fibroblast growth factor-23 (FGF23) level that… Expand
ConditionsChronic Kidney Diseases
InterventionDrug
The challenge of controlling phosphorus in chronic kidney disease.
  • J. Cannata-Andía, K. Martin
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2016
TLDR
Despite phosphate binding agents having proved to be effective in reducing serum phosphorus, their ultimate effects on clinical outcomes remain controversial and well-designed, large-scale, placebo-controlled studies are needed to definitively prove that the reduction of serum phosphorus by phosphate binders improves clinical outcomes. Expand
Bone and Mineral Disorders
TLDR
The discovery of FGF23 has changed the understanding of abnormal phosphorus and vitamin D metabolism in CKD and reinforced the need to reconsider the risks and benefits of using activated vitamin D and to determine the optimal doses to treat CKD-mineral and bone disorder (CKD-MBD). Expand
Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
TLDR
When and how to optimize phosphate control to provide the best clinical outcomes in CKD-MBD patients is discussed. Expand
Determination of IL-35, PTH, Ferritin and Other biochemical. Parameters in sera of Iraqi Men with chronic kidney failure
TLDR
The present study concludes that IL-35 is a strong biochemical marker for Iraqi men with CKF and indicated the positive relationship between (PTH, Na, K, PO4 ) and chronic kidney failure, and the negative relationship between Ferritin, albumin, hemoglobin, HCO3 and Other biochemical. Expand
Efficacy of hemodialysis and other therapeutic measures in controlling hypocalcemia, hyperphosphatemia and elevated ALP in a group of patients with end-stage renal disease
TLDR
Despite the progression in modalities of treatment of CKD, including hemodialysis, the correction of its associated metabolic disturbances remains a challenge especially hyperphosphatemia and to lesser extent hypocalcemia. Expand
Serum vitamin D and parathyroid hormone profiles in patients with various stages of renal disease.
TLDR
Depletion of serum vitamin D concentration accompanied with the development of severe secondary hyperparathyroidism with the progression in kidney disease was exhibited in Saudi patients with kidney disease. Expand
Vitamin D, calcium, and cardiovascular mortality: a perspective from a plenary lecture given at the annual meeting of the American Association of Clinical Endocrinologists.
  • P. Miller
  • Medicine
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2011
TLDR
While no solid scientific evidence validates that serum vitamin D levels between 15 and 70 ng/mL are associated with increased cardiovascular disease risk, stronger but inconsistent evidence shows an association between calcium supplementation greater than 500 mg daily and an increase in cardiovascular diseaserisk. Expand
Chronic Kidney Disease-Mineral Bone Disorder in Diabetes Mellitus Patients
TLDR
Disturbances in mineral and bone metabolism are prevalent in CKD and are an important cause of decreased quality of life, cardiovascular morbidity and mortality; these disturbances settle in earlier and have a more severe evolution in DM patients. Expand
Patient education for phosphorus management in chronic kidney disease
TLDR
Phosphorus binders are associated with a clear survival advantage in CKD patients, overcome the limitations associated with dietary phosphorus restriction, and permit a more flexible approach to achieving normalized phosphorus levels. Expand
Association of ORAI 1 Genetic Polymorphism with Serum Calcium and Phosphorus Levels in Non-dialysis Chronic Kidney Disease Patients : A Case-control Study
Background As chronic kidney disease (CKD) is a silent killer, it is now a global concern to find out the possible causes by genetic and biological markers. In the earlier stages of CKD, serumExpand
...
1
2
3
...

References

SHOWING 1-10 OF 13 REFERENCES
Chronic kidney disease mineral and bone disorder in children
TLDR
Newer therapeutic agents, including calcium-free phosphate binding agents and new vitamin D analogues, effectively suppress serum PTH levels while limiting intestinal calcium absorption and may provide future therapeutic alternatives for children with CKD. Expand
Chronic kidney disease-mineral-bone disorder: a new paradigm.
TLDR
The term CKD-mineral and bone disorder (CKD-MBD) should be used to describe the broader clinical syndrome that develops as a systemic disorder of mineral and bone metabolism as a result of CKD, and the pathogenesis and clinical manifestations are described in detail. Expand
Association of serum phosphate with vascular and valvular calcification in moderate CKD.
TLDR
Higher serum phosphate concentrations are associated with a greater prevalence of vascular and valvular calcification in people with moderate CKD, and it remains to be determined whether lowering phosphate concentrations will impact calcification risk in the setting of kidney disease. Expand
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.
TLDR
Compared with calcium-based phosphate binders, sevelamer is less likely to cause hypercalcemia, low levels of PTH, and progressive coronary and aortic calcification in hemodialysis patients. Expand
Phosphate Binder Impact on Bone Remodeling and Coronary Calcification – Results from the BRiC Study
TLDR
There was no difference in CAC progression or changes in bone remodeling between the calcium and the sevelamer groups. Expand
Serum phosphate levels and mortality risk among people with chronic kidney disease.
TLDR
Elevated serum phosphate levels were independently associated with increased mortality risk among this population of patients with chronic kidney disease and were associated with a significantly increased risk for death. Expand
Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.
TLDR
Baseline CAC score was a significant predictor of mortality after adjustment for age, race, gender, and diabetes with increased mortality proportional to baseline score with greater risk of death for patients treated with calcium-containing phosphate binders persisted after full multivariable adjustment. Expand
Coronary artery calcification in patients with CRF not undergoing dialysis.
TLDR
CAC is already present in the early phase of CRF; the prevalence is greater in patients with CRF than in controls, but less than that reported in dialysis patients. Expand
Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.
TLDR
New hemodialysis patients with no evidence of coronary calcification showed little evidence of disease development over 18 months independent of phosphate binder therapy, however, subjects with evidence of at least mild coronary calcify had significant progression at 6, 12, and 18 months. Expand
Vascular calcifications, vertebral fractures and mortality in haemodialysis patients
TLDR
Positive associations between vascular calcifications, vertebral fractures and mortality have been found in patients on haemodialysis. Expand
...
1
2
...